NCT05552183View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions

Hepatic Impairment

Interventions

DRUG

oral dose of 200 mg pacritinib twice daily (BID)

Subjects will receive 200 mg BID pacritinib for 14 days.

Trial Locations (2)

32809

Site 2, Orlando

78215

Site 1, San Antonio

Sponsors

Lead Sponsor

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

CTI BioPharma

INDUSTRY